Humira(CF) pen 40 MG/0.4 MLS
Ended Awarded
- Contract number
- SPE2DB25FG9P1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,542
Award facts
- Contract value 100% obligated
- $3,541.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,541.91 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 10, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-competitive award under an existing contract vehicle and will be performed at the vendor's Conshohocken, Pennsylvania facility. HUMIRA (adalimumab) is a widely-used biologic medication for treating autoimmune conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis, making this order consistent with the Defense Logistics Agency's medical supply requirements for military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion contract vehicle valued through December 2026 that serves as the primary pharmaceutical support mechanism for global military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains significant federal contracting capacity and regularly fulfills DLA medical procurement needs for specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The company's inclusion in the DLA's planned Pharmaceutical Prime Vendor Global Program Generation V contracts underscores its capability to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FG9P1?
SPE2DB25FG9P1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 10, 2025.
How much is contract SPE2DB25FG9P1 worth?
The government has obligated $3,542 on SPE2DB25FG9P1.
Is contract SPE2DB25FG9P1 an order under another contract?
Yes. SPE2DB25FG9P1 is a delivery order under SPE2DB22D1103, an indefinite delivery contract.
Was contract SPE2DB25FG9P1 competed?
The extent of competition for SPE2DB25FG9P1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award